NeOnatal Vascular Access (NOVA) study: an observational audit of neonatal vascular access complications
The support and management of neonatal conditions rely upon stable vascular access for administration of lifesaving fluids, medications, nutrition and blood products. However VAD use is not without risk, with complications including infections, thrombosis, occlusion and extravasation frequently resulting in device failure and significant patient harm. It is estimated that greater than 50% of neonatal peripheral VAD, and 35% of peripherally inserted central catheters result in complications and device failure. In addition, a recent investigation (August D et al. 2019), has highlighted that successful VAD insertion may require several attempts, empathising another area for clinical evaluation.
NOVA is prospective audit, conducted over three months at one of Brisbane's largest tertiary neonatal units. NOVA will investigate neonatal VAD management and associated complications. Outcomes include complications leading to failure and incompletion of therapy: catheter-associated blood stream infection, dislodgement/migration and infiltration. Additionally, complications related to skin injury will also be considered such as: erythema, skin tear, tension injury/blister, and pressure injury.
Investigation Team:
Colette McIntyre, Royal Brisbane and Women's Hospital; Deanne August, Griffith University; Linda Cobbland, Royal Brisbane and Women's Hospital, Gill Lack, Royal Brisbane and Women's Hospital; Katie Foxcroft, Royal Brisbane and Women's Hospital; Nicole Marsh, Royal Brisbane and Women's Hospital; Patricia Smith, Royal Brisbane and Women's Hospital; Dr Karen New, University of Queensland; Mari Takashima; Griffith University; Dr Pieter Koorts, Royal Brisbane and Women's Hospital; Dr Adam Irwin, University of Queensland; and Dr Amanda Ullman, Griffith University
Funding for this study was received from Royal Brisbane and Women's Hospital Foundation.
https://www.sciencedirect.com/science/article/pii/S1355184118301911?via%3Dihub
